Navigation Links
Anti-inflammatory drug may fight breast cancer
Date:5/5/2011

The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report at the IMPAKT Breast Cancer Conference in Brussels.

The results of a randomized trial in 45 patients with primary invasive breast cancer showed that the drug --which is currently used to treat arthritis and other painful conditions-- clearly induced an anti-tumor response at the molecular level.

"This is exciting because it means that a medication already used to treat other diseases may be efficient in the adjuvant treatment of breast cancer as well," said lead researcher Juergen Veeck, from Maastricht University Medical Centre in The Netherlands.

Celecoxib is a member of a class of drugs known as selective COX-2 inhibitors. These drugs directly target COX-2, an enzyme responsible for inflammation and pain.

"We were pleased that the results from our clinical trial largely confirmed the existing data from several pre-clinical studies by showing that COX-2 inhibition leads to changes in cell proliferation, apoptosis, and extracellular matrix biology in primary breast cancer tissues," Dr Veeck said.

His group studied patients who were scheduled to have surgery to remove their cancer. Prior to surgery, patients were randomly assigned to receive either 400 mg celecoxib twice daily for two to three weeks, or control treatment, which was either an inactive placebo or no treatment.

The researchers analyzed the expression of particular genes in samples from the tumors before and after treatment. Other tests were performed to determine changes in proliferation and apoptosis (programmed cell death).

After treatment 1,109 genes were significantly up-regulated and 556 genes were significantly down-regulated in celecoxib-treated breast cancer tissues when compared to control treatment, they found.

Genes involved in cell proliferation, cell cycle, apoptosis, extracellular matrix biology and inflammatory immune responses were particularly affected.

"Even short-term treatment with celecoxib sets up transcriptional programs supporting anti-tumor activity in primary breast cancer tissues," the researchers say.

The treatment period in this preliminary study was not long enough to see a significant change of tumor size or histological grade, Dr Veeck and colleagues note. "For now we can only speculate that a longer treatment with celecoxib would have resulted in measurable tumor shrinkage as well."

"Celecoxib and other 'coxib' drugs are generating some excitement as future breast cancer therapy since they are a well-established medication for other diseases, with relatively low toxicity and high safety profiles," Dr Veeck said.

"Until now, most clinical results suggested coxibs may be useful for cancer prevention. However, our study provides evidence that they may also be efficient as cancer treatments, at least in breast cancer."

Because there are close links between COX-2 expression and Her2 status and aromatase levels in breast cancer, the Dutch group suggests that researchers should now investigate coxibs in combination with trastuzumab or aromatase inhibitors.

Commenting on the study, which he was not involved in, Dr Stephen Johnston, from the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, noted that this small randomized clinical trial looked at changes in gene expression after short-term exposure to celecoxib, and anti-inflammatory drug that has been thought to have anti-cancer properties.

"The research used biopsies before and after 2 weeks of exposure to the drug or placebo to show the various genes that were altered by the drug, although these did not alter the way the cancer cells grew. Therefore, this can be a useful model in which to test exactly what a drug does in human breast cancer tissue in-vivo."


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Non-steroidal anti-inflammatory drugs linked to increased risk of erectile dysfunction
2. Anti-Inflammatory Helps Treat Bacterial Meningitis: Study
3. Grant for rotten eggs anti-inflammatory research
4. New research reinforces anti-inflammatory properties of tart cherries
5. Two New Phytochemicals with Anti-Inflammatory Activity Found in Noni Fruit
6. Physician's Pain Relief Cream Includes Patented Anti-inflammatory in New Formula
7. Prozac and Celexa exhibit anti-inflammatory effects
8. Obese Pregnant Women May Have Tougher Time Fighting Infections
9. Bone Drug Plus Statin Better at Fighting Plaque in Aorta: Study
10. New technique extends cancer-fighting cells potency in melanoma patients
11. $4.8 million study will fight child obesity in California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: